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Interpretation of Quality-of-Life Scores
Mary-Margaret Chren1
Patients’ reports of their experience with illness are a key health outcome, but 
scores that measure these reports can be difficult to interpret. Skindex-29 measures 
skin-related quality of life reliably and validly. In this issue, Prinsen and colleagues 
compare patients’ responses to “anchor” questions with their Skindex scores to 
derive clinically meaningful scores for the subscales of Skindex-29. The cutoff scores 
identify patients whose skin diseases severely affect their quality of life.
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Clinicians routinely interpret clinical 
measurements such as blood pressure 
or hematocrit: almost without think-
ing, we “know” what the values mean 
for a patient’s health. This knowledge 
is based on our experience caring for 
many patients and on what we have 
learned from teachers and reading.
For many measurements in clinical 
studies we lack this intuition, however. 
One of the original studies of finasteride 
for benign prostatic hyperplasia graphi-
cally illustrates this point (Lydick and 
Epstein, 1993; Gormley et al., 1992). 
Compared with placebo, the drug 
improved urine flow by an average of 
3 ml/second—a rather bland finding, 
to be sure—until a subsequently pub-
lished epidemiological study found that 
for men aged 40–74 typical urine flow 
rates decline approximately 0.2–0.3 ml/
second per year of life (Girman et al., 
1993). We can now interpret the real-
world effect of finasteride: on average, 
it restores a man’s urinary flow to what 
it was 10–15 years earlier.
Interpreting measurements such 
as urine flow is relatively straight-
forward compared with interpreting 
more abstract health outcomes such 
as scores of patients’ reports concern-
ing their experience with illness. The 
actual measurement of psychometric 
constructs is a highly advanced and rig-
orous science, and substantial progress 
has been made in applying this science 
to clinical medicine (Both et al., 2007). 
Dermatology has lagged somewhat in 
rigorous studies to interpret the mean-
ing of psychometric scores, however, 
and these scores remain unfamiliar to 
most researchers and clinicians. It is 
highly fitting that in what the Journal 
has designated the Year of the Patient 
(Bergstresser, 2010), this issue contains 
a good example of a study to facilitate 
interpretation of one measurement of 
patients’ experience of illness (Prinsen 
et al., 2010). In this Commentary, I 
describe briefly where we are with 
respect to measuring patients’ reports, 
summarize the major findings of that 
article, and project where we might go 
next to advance this important aspect of 
clinical research.
Patients’ reports of their experience 
with illness are a key health outcome. 
This observation is especially true for 
skin diseases, which do not typically 
affect survival, laboratory values, or eas-
ily measured clinical changes. In fact, 
patients’ reports are arguably an essential 
health outcome for dermatology because 
skin diseases (unlike most “internal” dis-
eases) can change appearance, and they 
may have psychological and functional 
effects that cannot be assessed except 
through patients’ reports.
Most scientific work on the assess-
ment of patients’ experience with cuta-
neous illness has focused on instruments 
that measure skin-related quality of life. 
Generic and disease-specific quality-of-
life instruments have been developed 
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for dermatology and found to have reli-
ability (i.e., they give the same result 
when quality of life is the same), validity 
(i.e., they measure quality of life), and 
responsiveness (i.e., they change when 
quality of life changes) (Both et al., 
2007). But fewer data exist on the inter-
pretability of scores with these instru-
ments. What does a given score mean? 
Does the score indicate severe effects 
of the disease or mild effects? What 
do changes in scores mean? Have the 
effects of the disease changed substan-
tially or only by a small amount?
By simply examining the content of 
questions and patients’ responses, one 
can begin to interpret a score, espe-
cially for a single question. For exam-
ple, a typical item in Skindex-29 is “I 
am embarrassed by my skin condition.” 
Response choices and corresponding 
scores are “never” (0), “rarely” (25), 
“sometimes” (50), “often” (75), or “all 
the time” (100). If a patient’s item score 
is 25, we understand that he or she is 
only rarely embarrassed by the skin 
problem. This “content-based” interpre-
tation is less straightforward for scales 
that are derived from multiple items, 
however. Skindex is a multiscale index 
for which subscores are reported for 
Symptoms, Emotions, and Functioning. 
What can we do to put scale scores 
into context so that their meaning can 
be understood by clinicians?
A useful framework categorizes 
interpretation methods as either distri-
bution-based or anchor-based (Lydick 
and Epstein, 1993). Distribution-based 
interpretations are based on the statis-
tical distributions of scores in a given 
population. For example, I can begin to 
understand the magnitude of the effect 
my patients report by comparing their 
scores with those of a “normative” sam-
ple of unaffected persons (or of persons 
known to be severely affected). A recent 
paper using a distribution-based method 
reported that the distribution of respons-
es to Skindex-29 could be clustered into 
statistically distinct categories based 
on the degree of reported quality-of-
life effect (Nijsten et al., 2009). For the 
Symptoms subscale, for example, the 
categorization permitted cutoff values 
that corresponded to “very little” effect 
(≤3), “mild” effect (4–10), “moderate” 
effect (11–25), “severe” effect (26–49), 
and “extremely severe” effect (≥50).
Anchor-based interpretations, on 
the other hand, are made when scores 
are compared, or anchored, to other 
clinical results. A commonly used 
anchor is the response of patients to 
global rating questions that are them-
selves easily interpreted; in the cur-
rent study, Prinsen et al. (2010) use this 
strategy to help interpret the meaning 
of Skindex-29 scores. The investigators 
administered Skindex-29 and a variety 
of anchor questions to a large sample of 
dermatology outpatients. The analyses 
compared Skindex subscale scores to 
patients’ responses to three major types 
of anchors: global questions about 
aspects of health-related quality of life, 
a question about the patient’s estimate 
of the clinical severity of his or her skin 
disease, and results on a standardized 
measure of psychiatric morbidity. For 
each of the anchors, the investigators 
predefined scores that indicate “severe” 
effects. They then determined the mini-
mum Skindex scores (cutoff scores) 
that were most accurate in distinguish-
ing patients who did or did not report 
severe effects. Skindex cutoff scores for 
severely impaired skin-related quality 
of life were ≥37 for Functioning, ≥39 
for Emotions, and ≥52 for Symptoms.
Prinsen et al. (2010) used receiv-
er-operating characteristic (ROC) 
methodology to determine the accu-
racy of the cutoff score. ROC curves 
are commonly used to display the 
ability of a diagnostic test to distin-
guish between people with or without 
the condition of interest by describ-
ing the performance of the test as the 
relation between the true-positive rate 
and the false-positive (1-specificity) 
rate (Deeks, 2001). Different cutoffs of 
scores have different sensitivities and 
specificities in relation to the criterion 
in question (e.g., global health-related 
quality of life). To determine cutoffs for 
Skindex scores, the authors selected 
the cutoff that maximized the sum of 
sensitivity and specificity (Fluss et al., 
2005). This decision does not ipso facto 
have clinical meaning but requires a 
judgment about the relative benefits 
and liabilities of accurately detecting 
and not missing severe quality-of-life 
effects. With justification, the authors 
could also have chosen different lev-
els of sensitivity and specificity (e.g., to 
maximize true positives at the expense 
of also increasing the numbers of false 
positives). Their strategy seems reason-
able, however. Lowering the Skindex 
Symptom cut-off score for severe 
quality-of-life effects from 52 to, say, 
45 would have detected more patients 
with severe Symptom quality-of-life 
effects as measured by the global item, 
but also would have labeled some 
patients as severely affected who in 
fact did not have severe effects as mea-
sured by the global item.
I look forward to seeing more 
results from this important and careful 
study, particularly the cutoff scores for 
mild and moderate degrees of effect, 
as determined by the anchors. Such 
results would permit us to interpret 
changes in scores if, for example, a 
group of patients changed from “mod-
erate” quality-of-life effects to “mild” 
effects over time or after an interven-
tion. They would also permit a more 
in-depth comparison to the Skindex-29 
cutoffs derived from the distribution 
method described above (Nijsten et 
al., 2009). Although the results for the 
interpretation of “severe” quality-of-life 
effects are similar in the two studies for 
Symptoms and Functioning, the cut-off 
for severe Emotional effects in the cur-
rent study (≥39) would be classified as 
indicating only moderate effects in the 
distributional study.
Clinical Implications
•  Tools to measure patients’ reports of their experiences with illness must 
measure accurately, and the results must be interpretable.
•  Survey instrument scores are often not meaningful because they are 
unfamiliar and not empirically derived or clinically based.
•  Information about interpretation of quality-of-life scores provides a 
basis for their more widespread use in clinical medicine and research.
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Using different anchors can inform 
interpretation even more. Prinsen et 
al. (2010) determined Skindex cut-
off scores for patients’ judgments of 
severity of their disease and for their 
responses to a measure of psychiatric 
morbidity. In other work, changes in 
generic health-related quality of life 
have been correlated with the impact 
of stressful life events, with being 
diagnosed with chronic diseases, with 
resource utilization, and with survival 
(Deyo and Patrick, 1995).
Clinically meaningful interpre-
tations of quality-of-life scores are 
important to patients, clinicians, 
researchers, public health personnel, 
and policy makers. These individuals 
will be comfortable with these scores 
only when they become familiar (Deyo 
and Patrick, 1995), which will require 
their routine use in clinical research 
and possibly in practice (Chren, 2005). 
But routine use alone is not sufficient. 
Even if widely interpretable scores 
are obtained and reported in clinical 
trials, the results may not be used to 
modify the conclusions (Contopoulos-
Ioannidis et al., 2009). Ultimately, 
to improve clinical decision making, 
an explicit commitment to including 
patients’ perspectives is necessary in 
clinical research.
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Common Links among the 
Pathways Leading to UV-Induced 
Immunosuppression
Gary M. Halliday1
In this issue, Sreevidya et al. demonstrate unexpected similarities in the down-
stream events of two molecular triggers of UV-induced immunosuppression. 
Both platelet-activating factor and cis-urocanic acid produced reactive oxygen 
species (ROS). Blocking both photoproducts reduced UV-induced genetic dam-
age. Vitamin D, another immunosuppressive photoproduct, does not share this 
property but instead enhances DNA repair. This study therefore links ROS and 
genetic damage with two molecular triggers of UV immunosuppression.
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UV radiation from the sun causes the 
majority of skin cancers in humans. 
Nonmelanoma skin cancer is the 
most prevalent type of cancer in light-
skinned Caucasians, and in Australia 
it is three times more common than 
all other types of cancers combined. 
UV radiation’s potent carcinogenicity 
results from its dual action: (i) it causes 
genetic damage that can result in 
mutations that disturb cellular behav-
ior and therefore cause cancer and (ii) 
it triggers immunosuppression. The lat-
ter prevents the development of pro-
tective immunity to mutated proteins, 
allowing cancer cells to develop and 
grow unhindered by immunity. For 
many years, reductionist approaches to 
identifying the effects of UV radiation 
on immunity have found a large num-
ber of distinct immune-modulating 
events to be instigated by UV radia-
tion. However, a new report (Sreevidya 
et al., 2010, this issue) suggests a com-
mon link among several of the immune 
suppressive events activated by UV 
and the DNA damage that can lead to 
mutations, providing novel insight into 
the interactions between UV-induced 
immunosuppression and genetic dam-
age, which are required for skin cancer 
development.
UV radiation has been shown to ini-
tiate a number of molecular pathways 
that can lead to immunosuppression. 
It is intriguing that despite these dif-
ferent pathways, inhibition of a single 
pathway is sufficient in many studies 
to prevent UV immunosuppression 
and (often) reduce photocarcinogen-
esis. This suggests that immunosuppres-
sion may be fragile, requiring multiple 
